AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Collegium Pharmaceutical ... (COLL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

29.75

-0.16 (-0.53%)

At close: Feb 20, 2025, 3:59 PM

29.75

0.02%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	28.83
Market Cap	959.28M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.34
PE Ratio (ttm)	12.71
Forward PE	n/a
Analyst	Buy

Ask	30.63
Volume	156,699
Avg. Volume (20D)	419,059
Open	29.73
Previous Close	29.91
Day's Range	29.67 - 30.26
52-Week Range	28.39 - 42.29
Beta	undefined

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 7, 2015

Employees 197

Stock Exchange NASDAQ

Ticker Symbol COLL

Website https://www.collegiumpharma.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 47.92% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Collegium Pharmaceutical Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+14.41%

Collegium Pharmaceutical shares are trading higher... Unlock content with Pro Subscription

6 months ago

+10.63%

Collegium Pharmaceutical shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy announced a price target of $47.

News

2 months ago · seekingalpha.com

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of J...